EULAV Asset Management decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 20.3% during the first quarter, Holdings Channel reports. The firm owned 137,000 shares of the medical research company’s stock after selling 35,000 shares during the period. EULAV Asset Management owned approximately 0.06% of Edwards Lifesciences Corporation worth $12,888,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quadrant Capital Group LLC boosted its position in shares of Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the period. YorkBridge Wealth Partners LLC purchased a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at about $110,000. NEXT Financial Group Inc boosted its position in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the period. Advantage Investment Management LLC purchased a new position in shares of Edwards Lifesciences Corporation during the fourth quarter valued at about $145,000. Finally, Crawford Investment Counsel Inc. purchased a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at about $207,000. 84.41% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation (NYSE EW) traded up 0.03% during trading on Friday, hitting $114.99. 1,548,830 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $113.46 and its 200 day moving average price is $98.41. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The firm has a market cap of $24.13 billion, a price-to-earnings ratio of 38.23 and a beta of 0.75.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.12. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The company had revenue of $883.50 million during the quarter, compared to analyst estimates of $776.51 million. During the same period last year, the firm posted $0.71 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 26.7% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “EULAV Asset Management Sells 35,000 Shares of Edwards Lifesciences Corporation (EW)” was originally posted by Financial Market News and is the property of of Financial Market News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.financial-market-news.com/2017/06/17/eulav-asset-management-sells-35000-shares-of-edwards-lifesciences-corporation-ew.html.

Several research analysts have issued reports on the stock. Vetr raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating and set a $111.50 target price for the company in a report on Tuesday, March 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, May 18th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price for the company. Finally, BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $120.38.

In other news, VP Patrick B. Verguet sold 10,000 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $114.88, for a total transaction of $1,148,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 284,221 shares of company stock valued at $31,023,158. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.